|
|
 |
|
Viewing report
|
|
|
|
The Pharmaceutical Market: Netherlands
Espicom Business Intelligence Ltd, Oct 2011, Pages: 82
THE PHARMACEUTICAL MARKET: THE NETHERLANDS - REVIEW
The Dutch government has introduced a mandatory health insurance scheme, which replaced the previous two-tier system and provides basic health insurance cover for acute care services, with a separate scheme for long-term medical care. The reforms have given health insurers a more prominent role in determining the level of Dutch healthcare spending and this has given rise to an even more competitive market environment for suppliers, as evidenced by the move towards a preferred supplier system.
Following Schering-Plough’s merger with Merck, the company announced it was to close three R&D sites in the Netherlands, leading to the loss of around 2,000 jobs. However, in May 2011, MSD reported that it had decided to reorganise its operations in Oss and that almost 500 research jobs would remain at the plant to focus on medicines for developed markets. The closure at Boxmeer went ahead as planned with the loss of around 35 jobs. MSD is still looking into an alternative solution for the facility in Scaijk.
In February 2011, the Ministry of Health, Welfare and Sport (VWS) announced it was putting the production facility of the Netherlands Vaccine Institute (NVI) in Bilthoven up for sale. The Institute had a long history of supplying vaccines to the Dutch population, but a change in policy means that this will now be carried out by the private sector. The sale of the Institute marks the end of one of the last remaining public vaccine facilities around the world.
Many new biologic drugs have been registered in the Dutch pharmaceutical market in the past few years. There are a number of biopharmaceutical companies present in the Netherlands. In February 2011, Johnson & Johnson completed its acquisition of Crucell, but the company will continue to operate independently. In June 2010, Fornix Biosciences sold its allergy division to ALK-Abelló.
ENHANCED STRATEGIC INTELLIGENCE
These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
- Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
- The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
Customers who bought this item also bought
The Pharmaceutical Market: Canada
The Pharmaceutical Market: Japan
The Pharmaceutical Market: Pakistan
The Pharmaceutical Market: Ireland
The Pharmaceutical Market: Ukraine
The Pharmaceutical Market: Indonesia
The Pharmaceutical Market: India
The Pharmaceutical Market: Thailand
The Pharmaceutical Market: Saudi Arabia
The Pharmaceutical Market: Latvia
|
|
|
|
